Animal Models of Disease, Part B, Volume 188 in the Methods in Cell Biology series, highlights advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Using C. Elegans as a model for Neurodegenerative disease: Methodology and Evaluation, Modelo Animal de Esclerosis Multiple: Encefalomielitis Autoimmune Experimental (EAE, New mouse model to study aneurysm development, Spinal Nerve Ligation: An Experimental Neuropathic Pain Model in Rats and Mice, Identifying therapeutic compounds for Autosomal Dominant Optic Atrophy (ADOA) through screening in the nematode C. elegans, Eµ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia, and much more.
Other chapters cover Purification and characterization of kidney-infiltrating leukocytes in a mouse model of lupus nephritis, Differences in intratumor innate lymphoid cell composition between orthotopic and spontaneous pancreatic mouse models, Assessing motor development and function in mouse models of neurodevelopmental disorders, Analysis of Gut Microbiota profile targeted to multi hypervariable regions of 16S rRNA in hypertensive heart failure rat model, and more.
Preface
Lorenzo Galluzzi, Fernando Aranda Vega, Aitziber Buque Martinez and Jose
Manuel Bravo-San Pedro
1. Using C. elegans as a model for neurodegenerative diseases: Methodology
and evaluation
Elena Caldero-Escudero, Silvia Romero-Sanz and Sergio De la Fuente
2. Animal model of multiple sclerosis: Experimental autoimmune
encephalomyelitis
Ana Muńoz-Jurado, Begońa Escribano and Isaac Tśnez
3. A new procedure to induce aortic aneurysms in mice
Raquel Rodrigues-Dķez, Antonio Tejera-Muńoz and Raśl R. Rodrigues-Diez
4. Spinal nerve ligation: An experimental model to study neuropathic pain in
rats and mice
Erick J. Rodrķguez-Palma, Itzel I. Ramos-Rodrķguez, Saśl Huerta de la Cruz,
Vinicio Granados-Soto and Maria Sancho
5. Identifying therapeutic compounds for autosomal dominant optic atrophy
(ADOA) through screening in the nematode C. elegans
Fivos Borbolis and Konstantinos Palikaras
6. E-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia
Iria Fernandez Botana, Susanne Gonder, Vanessa Klapp, Etienne Moussay and
Jerome Paggetti
7. Purification and characterization of kidney-infiltrating leukocytes in a
mouse model of lupus nephritis
Laura Amo, Hemanta K. Kole, Bethany Scott, Francisco Borrego, Chen-Feng Qi,
Hongsheng Wang and Silvia Bolland
8. Differences in intratumor innate lymphoid cell composition between
orthotopic and spontaneous pancreatic mouse models
Sara Lamorte, Alisha R. Elford, Douglas C. Chung, Kiichi Murakami, Tracy L.
McGaha and Nicolas Jacquelot
9. Assessing motor development and function in mouse models of
neurodevelopmental disorders
Lauren Dierdorff, Marta Garcia-Forn, Alexa von Mueffling and Silvia De Rubeis
10. Analysis of the gut microbiota profile targeted to multiple hypervariable
regions of 16S rRNA in a hypertensive heart failure rat model
Javier Modrego, Adriana Ortega-Hernįndez, Silvia Sįnchez-Gonzįlez, Arturo
Corbatón-Anchuelo and Dulcenombre Gómez-Garre
11. Animal models of neglected parasitic diseases: In vivo multimodal imaging
of experimental trypanosomatid infections
Jean Marc Tsagmo Ngoune, Brice Rotureau and Estefanķa Calvo Alvarez
12. Intracranial graft of bioresorbable polymer scaffolds loaded with human
dental pulp stem cells in stab wound murine injury model
Irene Manero-Roig, Yurena Polo, Beatriz Pardo-Rodrķguez, Jon Luzuriaga, Ruth
Basanta-Torres, Daniel Martķn-Aragón, Irene Romayor, Sara Martķn-Colomo,
Joana Mįrquez, Laura Gomez-Santos, Frédéric Lanore, Yann Humeau, Gaskon
Ibarretxe, Cristina Eguizabal,
Aitor Larrańaga and Jose Ramon Pineda
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome La Sapienza. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract Miguel Servet tipo I by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo. Aitziber Buqué is currently a Post-Doctoral Associate with the Galluzzi Lab, in the Department of Radiation Oncology at Weill Cornell Medical College (New York), where she investigates innate and acquired mechanisms of resistance to immunotherapy in HR+ breast cancer and radiotherapy as a means to overcome them. Prior to joining the Galluzzi Lab (2018), Aitziber was a Post-Doctoral Associate with the Kroemer Lab in the Cordeliers Research Center (Paris, France; 2014-2018), after receiving her M.Sc. in Bioinformatics and Computational Biology (2006) from the Complutense University (Madrid, Spain) and her Ph.D. in Biomedicine (2013) from the BioCruces Research Institute (Barakaldo, Spain). Aitziber has a long-standing interest in the immunological mechanisms controlling cancer progression and response to treatment. Jose Manuel Bravo-San Pedro is currently a researcher at the Department of Physiology of the Complutense University of Madrid thanks to a Ramon y Cajal contract grant. He got his Ph.D. in biochemistry, cellular biology and genetics from the University of Extremadura (Caceres, Spain) in 2011, and he did a post-doctoral stage in the laboratory of Prof. Guido Kroemer. His main research interests have always been linked to autophagy, addressing this cellular process associated with neurodegenerative diseases or cancer and recently obesity and specifically related to problems in the correct functioning of the cilium. He is co-inventor of two patents and co-author of 110 publications indexed in PubMed in prestigious international journals, with h-index 45 and 23768 cites (Dec 2022).
